The company has also appointed David DeMagistris as senior vice president of pharmaceutical sciences and Jean Silveri as senior vice president of general counsel.
Prior to joining Cerulean, Dr DeMagistris led strategic technology at GlaxoSmithKline, a provider of both clinical and commercial drug products. Ms Silveri joins Cerulean after serving as vice president and general counsel at ConjuChem Biotechnologies, where she was responsible for all legal and intellectual property matters of the company.
Alan Crane, CEO of Cerulean, said: “The name Tempo was focused solely on the temporal nature of our initial therapeutic approach, and the new name Cerulean better reflects the company’s broader aspiration to develop a wide range of important human medicines that will make a significant difference in the treatment of cancers and other diseases.”